Non-Interventional Study Investigating the Use of Golimumab (Simponi®) in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

Trial Profile

Non-Interventional Study Investigating the Use of Golimumab (Simponi®) in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Golimumab (Primary)
  • Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GO-NICE
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 08 Nov 2017 Results (n=244) of a post-hoc sub-analysis assessing Golimumab in biologic-naive patients with established ankylosing spondylitis, presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 08 Nov 2017 Results of a sub-analysis assessing Golimumab in biologic-naive patients (n=758), presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 17 Jun 2017 Results of subgroup analysis assessing effect of golimumab on biologic-naive patients presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top